FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215539785> ?p ?o ?g. }

• W3215539785 endingPage "140" @default.
• W3215539785 startingPage "133" @default.
• W3215539785 abstract "Pvs48/45 is a Plasmodium vivax gametocyte surface protein involved in the parasite fertilization process. Previous studies showed that Pvs48/45 proteins expressed in Escherichia coli (E. coli) and Chinese hamster ovary (CHO) cells were highly immunoreactive with sera from malaria-endemic areas and highly immunogenic in animal models. Here the immunogenicity in mice of three different vaccine formulations was compared.Recombinant (r) Pvs48/45 proteins were expressed in E. coli and CHO, purified, formulated in Alhydrogel, GLA-SE and Montanide ISA-51 adjuvants and used to immunize BALB/c mice. Animals were immunized on days 0, 20 and 40, and serum samples were collected for serological analyses of specific antibody responses using ELISA and immunofluorescence (IFAT). Additionally, ex-vivo transmission-reducing activity (TRA) of sera on P. vivax gametocyte-infected human blood fed to Anopheles albimanus in direct membrane feeding assays (DMFA) was evaluated.Most immunized animals seroconverted after the first immunization, and some developed antibody peaks of 106 with all adjuvants. However, the three adjuvant formulations induced different antibody responses and TRA efficacy. While GLA-SE formulations of both proteins induced similar antibody profiles, Montanide ISA-51 formulations resulted in higher and longer-lasting antibody titers with CHO-rPvs48/45 than with the E. coli formulation. Although the CHO protein formulated in Alhydrogel generated a high initial antibody peak, antibody responses to both proteins rapidly waned. Likewise, anti-Pvs48/45 antibodies displayed differential recognition of the parasite proteins in IFAT and ex vivo blockade of parasite transmission to mosquitoes. The CHO-rPvs48/45 formulated in Montanide ISA-51 induced the most effective ex vivo parasite blockage.Three out of six vaccine formulations elicited antibodies with ex vivo TRA. The CHO-rPvs48/45 Montanide ISA-51 formulation induced the most stable antibody response, recognizing the native protein and the most robust ex vivo TRA. These results encourage further testing of the vaccine potential of this protein." @default.
• W3215539785 created "2021-12-06" @default.
• W3215539785 creator A5005658261 @default.
• W3215539785 creator A5012223413 @default.
• W3215539785 creator A5013027733 @default.
• W3215539785 creator A5028156362 @default.
• W3215539785 creator A5050558064 @default.
• W3215539785 creator A5054659656 @default.
• W3215539785 creator A5089823757 @default.
• W3215539785 date "2022-01-01" @default.
• W3215539785 modified "2023-09-28" @default.
• W3215539785 title "Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice" @default.
• W3215539785 cites W1800786347 @default.
• W3215539785 cites W1833126320 @default.
• W3215539785 cites W1965244038 @default.
• W3215539785 cites W1970312160 @default.
• W3215539785 cites W1986169276 @default.
• W3215539785 cites W1990954596 @default.
• W3215539785 cites W2046583941 @default.
• W3215539785 cites W2069220164 @default.
• W3215539785 cites W2074905094 @default.
• W3215539785 cites W2077181684 @default.
• W3215539785 cites W2109582376 @default.
• W3215539785 cites W2114895863 @default.
• W3215539785 cites W2141913755 @default.
• W3215539785 cites W2157176215 @default.
• W3215539785 cites W2159943878 @default.
• W3215539785 cites W2171789634 @default.
• W3215539785 cites W2189403902 @default.
• W3215539785 cites W2260088396 @default.
• W3215539785 cites W2266850672 @default.
• W3215539785 cites W2280220883 @default.
• W3215539785 cites W2298951702 @default.
• W3215539785 cites W2341890653 @default.
• W3215539785 cites W2460575784 @default.
• W3215539785 cites W2463232551 @default.
• W3215539785 cites W2470813615 @default.
• W3215539785 cites W2536285012 @default.
• W3215539785 cites W2731408573 @default.
• W3215539785 cites W2791105224 @default.
• W3215539785 cites W2793236258 @default.
• W3215539785 cites W2883669154 @default.
• W3215539785 cites W2884464319 @default.
• W3215539785 cites W2885422062 @default.
• W3215539785 cites W2895657289 @default.
• W3215539785 cites W2895693270 @default.
• W3215539785 cites W2919101207 @default.
• W3215539785 cites W2940180668 @default.
• W3215539785 cites W2947349355 @default.
• W3215539785 cites W2971932246 @default.
• W3215539785 cites W3045657848 @default.
• W3215539785 cites W3139626855 @default.
• W3215539785 cites W1990994812 @default.
• W3215539785 doi "https://doi.org/10.1016/j.vaccine.2021.11.036" @default.
• W3215539785 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34802791" @default.
• W3215539785 hasPublicationYear "2022" @default.
• W3215539785 type Work @default.
• W3215539785 sameAs 3215539785 @default.
• W3215539785 citedByCount "2" @default.
• W3215539785 countsByYear W32155397852022 @default.
• W3215539785 countsByYear W32155397852023 @default.
• W3215539785 crossrefType "journal-article" @default.
• W3215539785 hasAuthorship W3215539785A5005658261 @default.
• W3215539785 hasAuthorship W3215539785A5012223413 @default.
• W3215539785 hasAuthorship W3215539785A5013027733 @default.
• W3215539785 hasAuthorship W3215539785A5028156362 @default.
• W3215539785 hasAuthorship W3215539785A5050558064 @default.
• W3215539785 hasAuthorship W3215539785A5054659656 @default.
• W3215539785 hasAuthorship W3215539785A5089823757 @default.
• W3215539785 hasBestOaLocation W32155397852 @default.
• W3215539785 hasConcept C104317684 @default.
• W3215539785 hasConcept C147483822 @default.
• W3215539785 hasConcept C150903083 @default.
• W3215539785 hasConcept C153911025 @default.
• W3215539785 hasConcept C159047783 @default.
• W3215539785 hasConcept C159654299 @default.
• W3215539785 hasConcept C173758957 @default.
• W3215539785 hasConcept C175656101 @default.
• W3215539785 hasConcept C203014093 @default.
• W3215539785 hasConcept C207001950 @default.
• W3215539785 hasConcept C22889606 @default.
• W3215539785 hasConcept C26291073 @default.
• W3215539785 hasConcept C2777775583 @default.
• W3215539785 hasConcept C2777863537 @default.
• W3215539785 hasConcept C2778048844 @default.
• W3215539785 hasConcept C2778371730 @default.
• W3215539785 hasConcept C2779997623 @default.
• W3215539785 hasConcept C2780478335 @default.
• W3215539785 hasConcept C2780868878 @default.
• W3215539785 hasConcept C32611913 @default.
• W3215539785 hasConcept C40767141 @default.
• W3215539785 hasConcept C54355233 @default.
• W3215539785 hasConcept C55493867 @default.
• W3215539785 hasConcept C59822182 @default.
• W3215539785 hasConcept C81885089 @default.
• W3215539785 hasConcept C86803240 @default.
• W3215539785 hasConcept C89423630 @default.
• W3215539785 hasConcept C99389464 @default.

• next